Company Analysis

Scienture Holdings, Inc. (SCNX)

Nasdaq: SCNX · Pharmaceutical Preparations · Commack, NY · filing with the SEC since 2007
Grade3.1
◀ Past 2.6● Present 2.1▶ Future 4.3
1 est.

The grade of Scienture Holdings, Inc.

Nine metrics read from its own filings, by tense
Headline grade
3.1/10
◀ Past2.625% of the headline
● Present2.135% of the headline
▶ Future4.340% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.5/10

Has it survived what it has been through?

18 warning events since 2017; the latest 2026-10-19.

weight 22% of this tense · 15th percentile among 497 sector filers · read for itself

From the record

Scienture Holdings, Inc.'s filings since 2017 show 18 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 13 times, the latest 2026-10-19); an auditor change (8-K item 4.01, the latest 2023-09-14); a late-report notice (Form NT 10-K or NT 10-Q, 4 times, the latest 2024-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.0/10

What has it actually done, year after year?

-26.8% a year over 8 filed years; profitable in 2 of 8.

weight 45% of this tense · 40th percentile among 323 sector filers · read for its customers

From the record

Scienture Holdings, Inc.'s 8 filed years say what it did: revenue went from $4 million in fiscal 2018 to $432 thousand in fiscal 2025, down 26.8% a year; it rose in 4 of 7 years; the deepest fall was 99% from fiscal 2020 to fiscal 2024; net income was positive in 2 of 8 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-26.8%bottom 12% of its family
  • the share of years revenue rosebottom 47% of its family
  • the share of filed years with a profittop 24% of its family
  • the deepest fall from a revenue peak99.2%bottom 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
1.5/10

How has it treated the people who own it?

SI estimate 1.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 15th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Scienture Holdings, Inc.'s shareholder treatment is put at 1.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.1/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
3.6/10

Is it financially healthy right now?

ROE -59%: lost 59¢ per shareholder dollar. Leverage 17%: owes 17¢ per asset dollar.

weight 45% of this tense · 36th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Scienture Holdings, Inc. lost about 59 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 17 cents per dollar of assets, and net share issuance: its share count grew 354.7% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 26% of its family
  • return on equitybottom 45% of its family
  • gross profit against assetsbottom 10% of its family
  • the share count against the year beforebottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
1.0/10

How strong is its position in its industry?

bottom 10% of 315 in its family; net margin -9618%.

weight 22% of this tense · 10th percentile among 315 sector filers · read for its customers

From the record

Scienture Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $432 thousand in fiscal 2025 ranks in the bottom 15% by size; a net margin of -9618% ranks in the bottom 11%; revenue growth of -65.2% a year over the last 3 filed years ranks in the bottom 5% (its annual reports).

What it rests on

  • revenue against the family$431,609bottom 15% of its family
  • net margin-9618.0%bottom 11% of its family
  • three-year revenue growth-65.2%bottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
0.7/10

What are the people in charge doing?

bottom 7% of 315 in its family for leadership; chief executive since 2026.

weight 33% of this tense · 7th percentile among 315 sector filers · read for its shareholders

From the record

Scienture Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Narasimhan, Mani (President & Co-CEO, as filed), filing under that title since 2026-03-12, 8 months (bottom 10% of its family); the 3 officers and directors filing in the last fifteen months have been on the record a median of 2.3 years (bottom 9%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 3 people in charge now (bottom 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge7 in three years among 3 peoplebottom 2% of its family
  • the median years the people in charge have filed2.3 yearsbottom 9% of its family
  • the chief executive's years on the record8 monthsbottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.3/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
4.2/10

How much room does it have to grow?

bottom 42% of 273 in its family for room to expand.

weight 33% of this tense · 42nd percentile among 273 sector filers · read for itself

From the record

Scienture Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 7.9% of its assets as net cash, bottom 22% of its family; cash from operations less capital spending is -3100% of revenue (bottom 15%); a gross margin of 76.8% (top 39%); research spending of 453.3% of revenue (top 30%) (its annual report).

What it rests on

  • cash less debt against assets7.9%bottom 22% of its family
  • cash from operations less capital spending against revenue-3100.0%bottom 15% of its family
  • gross margin76.8%top 39% of its family
  • research spending against revenue453.3%top 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.8/10

What could actually drive growth from here?

bottom 48% of 306 in its family for growth drivers.

weight 45% of this tense · 48th percentile among 306 sector filers · read for its customers

From the record

Scienture Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -65.2% a year over the last three filed years against -26.8% over all 8, slowing (bottom 15% of its family); the newest year grew 216.1% (top 10%); research spending grew -12.5% a year (bottom 27%); capital spending grew 0.8% a year (top 38%) (its annual reports). Scienture Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-38.4 points a yearbottom 15% of its family
  • the newest year's revenue growth216.1%top 10% of its family
  • three-year growth of research spending-12.5%bottom 27% of its family
  • three-year growth of capital spending0.8%top 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.5/10

Did its newest year beat what its own record pointed to?

bottom 35% of 233 in its family for expectations against reality.

weight 22% of this tense · 35th percentile among 233 sector filers · read for its shareholders

From the record

Scienture Holdings, Inc.'s newest year against its own record: revenue of $432 thousand in fiscal 2025 came in 2631.7% above the $16 thousand its prior three years' pace pointed to (top 3% of its family); net income of $42 million against a prior three-year average of $4 million (bottom 3%); a net margin of a loss larger than its revenue against more than its whole revenue before (bottom 6%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace2631.7%top 3% of its family
  • net income against the prior three years' averagefive times below its prior average or morebottom 3% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SCNX · research, not advice